Amy Welsh

Amy Welsh is a solution-driven, strategic biotech pharma leader with over 25 years of broad healthcare industry experience. Welsh is known for identifying critical insights and flawless execution and has experience in multiple commercial functions including sales operations and marketing expertise.

She was recently appointed Chief Executive Officer (CEO) of Aoraki Therapeutics, a newly established biotech focused on developing and commercializing innovative products to treat HPV-related cervical diseases and bladder cancer.

Prior to her CEO role at Aoraki Therapeutics, she served as Chief Commercial Officer at Agile Therapeutics, a women’s healthcare company, where she developed the strategic launch plan and successful commercialization of Twirla®, the only low-dose combined hormonal contraceptive patch on the market. Leveraging telehealth and specialty pharmacies during COVID restrictions, Welsh and her team drove national market share in the patch segment of contraceptives from 4% (Nov. 2023) to 28% (June 2024) in U.S. regions covered by Agile sales representatives.

Welsh’s success, which has been recognized with several industry awards, is due in part to her passion for learning products from the ground up and fostering internal and external partnerships that help educate HCPs and consumers on all the options while generating leadership and stakeholder buy-in. Undaunted by the big idea and facing down challenges are her own personal jet fuel.

She was a key member of the executive team that successfully sold Agile, returning a 350% premium to shareholders. The $45 million deal with Insud Pharma is expected to close in 3Q 2024. Throughout her tenure at Agile, Welsh has had frequent exposure to the investment community and was a valued partner to the Agile Board.

Welsh is proud of generating brand growth and awareness across Agile as well as prior companies. She has a comprehensive and multi-faceted commercial understanding of the pharmaceutical business, as well as device experience in men’s health.

Previously, Welsh served as Vice President of Marketing at Antares Pharma Inc. (acquired by Halozyme, Inc. in 2022). She also held various leadership roles at AstraZeneca in commercial and general management, helping grow some of its largest brands. Earlier in her career, she spent over a decade in the healthcare digital agency side, leading new business acquisitions and growing existing accounts.

Welsh holds a dual bachelor’s degree in marketing and English Literature from LaSalle University in Philadelphia.